Posters

Contralateral eye comparison study in MICS and MIGS: Trabectome® vs iStent inject® (one-year results)

Poster Details

First Author: J. Gonnermann GERMANY

Co Author(s):    E. Bertelmann   M. Pahlitzsch   A. Maier-Wenzel   N. Torun   M. Klamann        

Abstract Details

Purpose:

To compare the safety and efficacy profile after combined micro-incision cataract surgery (MICS) and micro-invasive glaucoma surgery (MIGS) with the ab interno trabeculectomy (Trabectome®) in one eye versus two iStent® inject devices in the contralateral eye in patients with open-angle glaucoma (OAG).

Setting:

Department of Ophthalmology, Charité-Universitätsmedizin Berlin

Methods:

This study included 27 patients who were treated with combined MICS and ab interno trabeculectomy (group I, Trabectome®) in one eye and with combined MICS and two iStent® inject decives (group II, GTS 400) in the fellow eye. Primary outcome measures included intraocular pressure (IOP) and glaucoma medication after 6 weeks, 3, 6 and 12 months follow-up. Secondary outcome measures were number of postoperative interventions, complications and best-spectacle corrected visual acuity (BCVA).

Results:

Mean preoperative IOP was 22.3 ± 3.7 mmHg in group I and 21.3 ± 4.1 mmHg in group II (P>0.05), which decreased to 15.6 ± 3.6 mmHg for Trabectome (p<0.001) and 14.0 ± 2.3 mmHg for iStent inject (p<0.001) at 12 months after surgery without a significant difference between the two groups (p>0.05). Glaucoma medication decreased from 2.1 ± 1.1 in group I and 2.0 ± 0.9 in group II (p>0.05) before surgery to 1.4 ± 1.3 in group I and 1.3 ± 1.2 12 months postoperatively (p>0.05). No vision-threatening complications such as choroidal effusion, choroidal hemorrhage, or infection occurred. In each group trabeculectomy had to be performed in 2 eyes due to insufficient IOP lowering effect.

Conclusions:

Ab interno trabeculectomy (Trabectome®) and iStent® inject were both effective in lowering IOP with a favourable and comparable safety profile in an intraindividual comparative study over a 12-months follow up in OAG. However, longer follow-up of these patients will be necessary to determine long-term outcomes and to evaluate significant differences.

Financial Disclosure:

NONE